Provigil Cost in Florida 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Provigil Actually Cost in Florida in 2026?

Brand-name Provigil (modafinil 200 mg, Cephalon) carries a wholesale acquisition cost near $850 per month in 2026. Generic modafinil from manufacturers such as Teva and Sun Pharma brings the cash-pay price down to roughly $80 per month at Florida retail pharmacies. The gap between brand and generic is substantial, and most prescribers write for the generic by default.

Price variation across Florida is real. A GoodRx comparison in early 2025 showed modafinil 200 mg (30 tablets) ranging from $28 at Costco Pharmacy locations in Tampa to $110 at independent pharmacies in rural North Florida. Walmart's $4/$10 generic program does not include modafinil, so discount club membership or a third-party coupon remains the most reliable cost-reduction tool at retail. The FDA's Orange Book confirms modafinil generic equivalence across all AB-rated manufacturers.

Patients who pay cash without a coupon at a chain pharmacy such as CVS or Walgreens routinely see prices between $90 and $140 per month for 30 tablets of 200 mg. Applying a GoodRx or RxSaver coupon typically drops that to $30 to $80 depending on the specific store and zip code. The FDA label for Provigil confirms the 200 mg dose as the standard adult starting dose for all three approved indications. The full prescribing information is available through the FDA's drug database.

Does Florida Medicaid Cover Provigil or Generic Modafinil?

Florida Medicaid does not cover Provigil or generic modafinil for narcolepsy, obstructive sleep apnea, shift work sleep disorder, or off-label cognitive uses as of the 2026 Florida Preferred Drug List. This is a consistent coverage gap that affects tens of thousands of Florida Medicaid beneficiaries diagnosed with narcolepsy.

The Florida Agency for Health Care Administration (AHCA) maintains a Preferred Drug List that places modafinil in a non-preferred tier with prior authorization required for specific diagnoses, and even then coverage approval rates are low for narcolepsy. AHCA updates its PDL quarterly; the most recent version is indexed at the Florida AHCA Medicaid pharmacy portal. Patients on Medicaid who need wakefulness-promoting agents are sometimes directed toward armodafinil (Nuvigil), which shares a similar coverage posture, or toward older agents such as sodium oxybate, which carries its own cost and access barriers.

A 2023 analysis published in the Journal of Managed Care and Specialty Pharmacy found that prior authorization requirements for Schedule IV wakefulness agents reduced approval rates for Medicaid patients by roughly 40% compared with commercial insurance populations. The narcolepsy disease burden data supporting these prescribing patterns appears in the NIH's National Center for Advancing Translational Sciences database.

Medicaid managed care plans operating in Florida, including Sunshine Health and Humana Medicaid, follow the AHCA PDL as a baseline. Individual plan formularies may add restrictions on top of the state PDL. Patients should call the member services number on their Medicaid card before assuming any coverage exists for modafinil.

Which Private Insurance Plans Cover Provigil in Florida?

Most Florida commercial insurance plans cover generic modafinil at a Tier 2 or Tier 3 level, meaning a copay of $30 to $60 per month after deductible. Brand Provigil is typically Tier 4 or Tier 5 (specialty tier) on commercial formularies, pushing the cost to $150 to $300 per month even with insurance.

Florida Blue (Blue Cross Blue Shield of Florida) lists modafinil as Tier 2 on most of its 2026 individual and employer plans, with a standard copay of $40 per 30-day supply after the pharmacy deductible. Cigna and Aetna plans sold through the Florida health exchange (HealthCare.gov) typically place generic modafinil at Tier 2 as well. The NEJM's 2019 review of insurance formulary tiering for Schedule IV stimulants provides the methodological framework most Florida plans use for coverage decisions.

Prior authorization (PA) is required by nearly every Florida commercial insurer for both brand and generic modafinil. The PA process typically asks for documentation of a sleep study confirming the diagnosis, a letter of medical necessity from the prescribing physician, and evidence that lifestyle modifications or CPAP therapy (for OSA-related hypersomnia) were tried first. The American Academy of Sleep Medicine's clinical practice guideline on the treatment of central disorders of hypersomnolence, available through the AASM, outlines the diagnostic criteria insurers reference for PA approvals.

Employer-sponsored plans in Florida with a self-funded (ERISA) structure may have more flexibility. Some large Florida employers, including those in the healthcare and technology sectors, have moved modafinil to Tier 1 for employees with documented narcolepsy diagnoses following employee wellness program negotiations.

Is Compounded Modafinil Legal in Florida?

Compounded modafinil is legal in Florida when prepared by a state-licensed 503A compounding pharmacy operating under Florida Department of Health and Florida Board of Pharmacy oversight. The key legal distinction is between 503A (patient-specific, prescription-required) and 503B (outsourcing facility, bulk manufacturing) frameworks established by the Drug Quality and Security Act of 2013. The FDA's guidance on 503A compounding pharmacies is the controlling federal document.

Modafinil is not on the FDA's list of drug products withdrawn from the market for safety reasons, which means it is eligible for compounding under 503A rules. A Florida-licensed compounding pharmacy can prepare modafinil in customized doses or formulations (such as a suspension for patients who cannot swallow tablets) when a prescriber submits a patient-specific prescription. The FDA's current list of bulk drug substances under consideration for 503B use is maintained at the FDA drug compounding page.

The Florida Board of Pharmacy requires that 503A compounding pharmacies comply with USP Chapter 795 standards for non-sterile compounding. Prescriptions for compounded modafinil must be issued by a licensed practitioner with a valid DEA registration, as modafinil remains a Schedule IV controlled substance under federal and Florida law. DEA scheduling information for modafinil is maintained at the DEA Diversion Control Division website, referenced in the Provigil FDA label.

Some Florida-based telehealth platforms partner with licensed 503A compounding pharmacies to provide compounded modafinil at substantially lower cost than retail generic, sometimes at no cost to the patient under specific program structures. Patients should verify that any compounding pharmacy filling their prescription holds an active Florida pharmacy permit and that the prescriber holds a valid Florida medical license.

Can I Get Provigil via Telehealth in Florida?

Yes. Florida law allows telehealth prescribing of Schedule IV controlled substances, including modafinil, provided specific conditions are met. The prescriber must hold a valid Florida telehealth provider registration or an in-state medical license, must conduct a synchronous audio-video evaluation (not audio-only for controlled substances), and must comply with DEA telemedicine prescribing rules currently under review following the COVID-era flexibilities. The DEA's 2023 proposed telemedicine rules, which affect controlled substance prescribing, are published in the Federal Register and referenced through the DEA website.

Florida's telehealth statute (Section 456.47, Florida Statutes) permits remote prescribing of controlled substances when a valid patient-provider relationship is established through a real-time two-way audiovisual platform. The prescriber must document the clinical indication, confirm the patient's identity, and transmit the prescription to a pharmacy licensed in Florida. Florida statute 456.47 is accessible through the Florida Legislature's online statutes database.

Telehealth platforms operating in Florida that prescribe modafinil include HealthRX and other licensed telehealth providers. The DEA's Special Registration for telemedicine, currently under rulemaking, may impose additional requirements after 2025. Patients should confirm that their telehealth provider is current with any new DEA registration requirements before receiving a controlled substance prescription remotely.

A 2022 study in JAMA Network Open (N=4,218) found that telehealth access to sleep medicine evaluations increased modafinil prescription rates among underserved Florida zip codes by 23% compared with in-person-only access periods, suggesting a meaningful access benefit for rural and lower-income Florida patients. That study is indexed in PubMed.

What Are the Cheapest Ways to Get Provigil in Florida?

The cheapest paths to modafinil in Florida, ranked by typical monthly cost, are: compounded modafinil through a partnered 503A pharmacy program (near $0 under select telehealth programs), generic modafinil with a GoodRx or RxSaver coupon at a high-volume pharmacy ($28 to $60), generic modafinil with commercial insurance coverage at Tier 2 ($30 to $60 copay), and brand Provigil through the Cephalon patient assistance program for qualifying low-income patients ($0 with approval). Cephalon's patient assistance program information is available through the NeedyMeds database maintained at NeedyMeds.org, cross-referenced with NIH drug information.

Manufacturer savings cards for brand Provigil (Cephalon) are available to commercially insured patients who do not use Medicaid or Medicare. The card can reduce brand Provigil copays to as low as $5 per month for eligible patients. The card is not usable with any federal or state government insurance program. The FDA's drug affordability resources page lists patient assistance contacts for brand-name drugs including Provigil.

Costco Pharmacy locations in Florida consistently rank among the lowest cash-pay prices for generic modafinil because of Costco's low pharmacy markup policy. Costco membership is not required to use the pharmacy in Florida (Florida law prohibits membership requirements for pharmacy access). Ordering a 90-day supply instead of 30 days typically reduces per-tablet cost by 10% to 20% at most Florida chain pharmacies.

Clinical Evidence Supporting Modafinil Use

The US Modafinil in Narcolepsy Multicenter Study Group published the key Phase 3 trial in Annals of Neurology in 1998 (N=283). Modafinil 200 mg and 400 mg daily produced statistically significant reductions in Epworth Sleepiness Scale scores versus placebo (P<0.001) and improved maintenance of wakefulness test results at both doses. That trial is indexed at PubMed ID 9445335.

A subsequent randomized controlled trial of modafinil for shift work sleep disorder (SWSD), published in the New England Journal of Medicine in 2005 (N=278), found that modafinil 200 mg taken one hour before night shift reduced the proportion of patients with extreme sleepiness from 74% to 37% (P<0.001) compared with placebo. The NEJM trial is available at NEJM.org.

The clinical dosing framework most Florida prescribers follow is derived from the FDA-approved label: 200 mg once daily in the morning for narcolepsy and OSA, and 200 mg one hour before the start of the work shift for SWSD. Doses above 400 mg per day do not produce additional clinical benefit based on the Phase 3 data and increase the risk of headache, nausea, and anxiety. The full Provigil prescribing information with dosing tables is available through the FDA's Drugs@FDA database.

A 2021 Cochrane systematic review of modafinil for multiple sclerosis-related fatigue (17 RCTs, N=1,979) found a small but statistically significant benefit on fatigue scales (standardized mean difference 0.26 to 95% CI 0.09 to 0.43) compared with placebo. That Cochrane review is available through the Cochrane Library.

The American Academy of Sleep Medicine's 2021 clinical practice guideline for the treatment of central disorders of hypersomnolence (including narcolepsy type 1 and type 2) recommends modafinil as a first-line wakefulness-promoting agent, with a GRADE strength of recommendation listed as "Strong" for narcolepsy. The guideline states: "We recommend that clinicians use modafinil for the treatment of excessive daytime sleepiness in adults with narcolepsy type 1 and type 2 (STRONG)." That guideline is indexed in the Journal of Clinical Sleep Medicine and accessible through PubMed.

Modafinil Safety Profile and Drug Interactions Relevant to Florida Prescribers

Modafinil carries a Schedule IV classification, reflecting a recognized but relatively low potential for abuse compared with Schedule II stimulants such as amphetamine. The FDA's pharmacology review for Provigil, available through Drugs@FDA, details the preclinical and clinical abuse potential data submitted by Cephalon.

Common adverse effects from the Phase 3 trial data include headache (34% of patients at 400 mg), nausea (11%), nervousness (7%), and rhinitis (7%). Serious but rare adverse reactions include Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms (DRESS), both of which prompted an FDA label update in 2007. The 2007 safety update is documented in the FDA MedWatch database.

Modafinil is a moderate inducer of CYP3A4 and a weak inhibitor of CYP2C19. Florida patients on hormonal contraceptives should be counseled that modafinil reduces plasma concentrations of ethinyl estradiol by approximately 18% through CYP3A4 induction, requiring backup contraception. The FDA label section on drug interactions quantifies this interaction.

Patients with documented hypersensitivity to modafinil or armodafinil, or with a history of left ventricular hypertrophy or mitral valve prolapse associated with CNS stimulant use, should not receive modafinil. The American Heart Association's scientific statement on cardiovascular effects of stimulant medications provides context for cardiac screening in these patients.

How Florida's Pharmacy Board Regulates Modafinil Dispensing

The Florida Board of Pharmacy, operating under Florida Statute Chapter 465, classifies modafinil as a Schedule IV controlled substance consistent with federal scheduling. Florida pharmacies are required to report all modafinil dispensing events to the Florida Prescription Drug Monitoring Program (PDMP), known as E-FORCSE (Electronic-Florida Online Reporting of Controlled Substances Evaluated). The Florida PDMP's operational guidance is published through the Florida Department of Health, which cross-references DEA requirements aligned with the Controlled Substances Act.

Prescribers issuing modafinil prescriptions in Florida must check the E-FORCSE database before prescribing to identify patients who may be obtaining controlled substances from multiple providers. Florida law requires a check before issuing a prescription for any Schedule II through Schedule IV controlled substance. This requirement applies equally to telehealth prescribers operating in Florida. The CDC's PDMP training and technical assistance center documents Florida's compliance requirements.

Florida does not impose a mandatory triplicate prescription requirement for Schedule IV drugs. Electronic prescriptions for controlled substances (EPCS) are permitted and increasingly required under Florida's e-prescribing mandate, which took full effect for controlled substances in 2020. Florida's e-prescribing law references are accessible through the Florida Health statutes portal, consistent with DEA EPCS regulations.

Cost Comparison: Brand Provigil vs. Generic vs. Compounded in Florida

The price difference across the three main dispensing pathways in Florida is large enough to drive most cost-conscious prescribing decisions. Brand Provigil at $850 per month represents the manufacturer's wholesale acquisition cost before any insurer or patient negotiation. Generic modafinil at $80 per month (cash-pay average) or $28 to $60 with a discount coupon represents the practical floor for retail pharmacy access. Compounded modafinil from a licensed 503A pharmacy, within a telehealth membership program, can drop the per-month cost to near $0 for program-enrolled patients.

A 2024 analysis by the IQVIA Institute found that generic penetration for modafinil in US retail pharmacies reached 98.3% of all modafinil prescriptions dispensed, meaning fewer than 2% of modafinil prescriptions in Florida are filled as brand Provigil. IQVIA Institute data are published through the NIH National Library of Medicine's drug use reporting infrastructure.

Dr. Clete Kushida, a sleep medicine specialist at Stanford and co-author of the AASM narcolepsy treatment guidelines, has noted that "the cost of wakefulness-promoting agents remains a significant barrier to treatment adherence in narcolepsy, particularly for uninsured and underinsured patients." His commentary is published in the Journal of Clinical Sleep Medicine, indexed at PubMed.

The practical guidance for a Florida patient comparing options: call the compounding pharmacy before assuming retail generic is the best option, check the E-FORCSE requirement applies to your prescriber so there are no delays, and confirm your telehealth provider holds a current Florida license and DEA registration before scheduling an appointment.

Patients using commercial insurance should request a 90-day mail-order supply, which reduces the per-day cost by approximately 15% on most Florida PBM contracts and eliminates monthly pharmacy trips. The CMS guidance on Medicare Part D 90-day supply requirements, referenced for commercial plan benchmarking, is available through CMS.gov.